Drug introduction of Sotagliflozin

Sotagliflozin (Sotagliflozin) is a new oral drug, a SGLT1/2 SGLT1/2 inhibitor, used to treat type 2 diabetes. Its unique mechanism of action involves dual inhibition of two different glucose transporters, including SGLT1, which is primarily found in the small intestine and is involved in the absorption of glucose from food, and SGLT2, which is primarily found in the renal tubules and is responsible for the reabsorption of glucose in the urine.

Through this mechanism of action, sogliflozin reduces the reabsorption of glucose in the urine and promotes the excretion of excess glucose through the urine, thereby effectively slowing down the rise in blood sugar and helping patients maintain a more stable blood sugar level.

Sogliflozin is mainly suitable for adult patients with type 2 diabetes, especially those who have poor response to other oral hypoglycemic drugs or who have cardiovascular risks. It exhibits effects beyond blood glucose regulation in diabetes management and may also have protective effects on the cardiovascular system and kidneys.

In terms of usage, sogliflozin is usually administered orally once daily. Doctors will develop an individualized medication plan based on the patient's specific situation and diabetes management needs.

However, patients need to pay attention to possible side effects when using soxgliflozin, including urinary tract infection, hypoglycemia, nausea, etc. In addition, for patients at risk of cardiovascular disease, doctors may comprehensively consider cardiovascular risk in the treatment plan and make corresponding adjustments.

Overall, sogliflozin, as an innovative diabetes treatment drug, provides patients with a new choice with multiple benefits such as hypoglycemic, cardiovascular and renal protection. Before use, patients should fully understand the characteristics of the drug and strictly follow the doctor's recommendations and monitoring to ensure safe and effective diabetes management.

xa0